Compare Merck & Co., Inc. (MRK) vs Rocket Lab USA Inc (RKLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Rocket Lab USA Inc — how do they compare? Merck & Co., Inc. trades at $148.15 (market cap $366.28B), while Rocket Lab USA Inc trades at $63.14 (market cap $42.12B). The key difference: Merck & Co., Inc. is far larger — about 8.7× Rocket Lab USA Inc's market cap, and Merck & Co., Inc. pays a 2.29% dividend while Rocket Lab USA Inc pays none. Which is the better fit depends on your goals.
| MRK | RKLB | |
|---|---|---|
Market Cap | $366.28B | $42.12B |
Sector | Health | Technology |
52-Week High | $156.43 | $150.23 |
52-Week Low | $77.60 | $39.48 |
Enterprise Value | $413.04B | $39.95B |
Dividend Yield | 2.29% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $156.71. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending, and maintains a robust gross profit margin of 72.97%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid a competitive pharmaceutical landscape.
The outlook for MRK is positive, driven by earnings momentum and strategic acquisitions, but risks include high valuation multiples like a P/E of 118.77 and regulatory pressures. Investors should weigh the company's solid cash flow and analyst support against potential market volatility and integration challenges from recent M&A activity.
Rocket Lab (RKLB) trades at $65.87, up 2.51% on the day, but remains in a bearish technical trend below key resistance levels. The company reported record Q2 2026 revenue of $234 million, up 62% year-over-year, yet continues to post significant net losses. Recent news highlights progress on the Neutron rocket and the pending Iridium Communications acquisition, but investor sentiment is mixed due to execution risks and delays.
The outlook hinges on successful Neutron deployment and path to profitability. Analysts see substantial upside with a $117.44 consensus target, but risks include cash burn, competitive pressure, and potential further launch delays. The stock offers high-growth potential for risk-tolerant investors betting on the space economy's expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Rocket Lab USA Inc
Rocket Lab USA, Inc. is an aerospace manufacturer and small-satellite launch service provider. The company specializes in developing rockets for orbital launch, including its flagship *Electron* vehicle, and is developing the next-generation, reusable *Neutron* rocket. Beyond launch services, Rocket Lab also offers satellite design, manufacturing, and spacecraft component solutions, positioning itself as an end-to-end provider for the space industry.
Read more on RKLB →
